By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Investment firm Jefferies today resumed coverage on eight molecular diagnostics, genetic testing, and life science tools firms.

Companies that Jefferies rated with a "Buy" are Myriad Genetics with a share price target of $26; Cepheid with a price target of $30; Gen-Probe with a price target of $75; Complete Genomics with a price target of $13; and Exact Sciences with a price target of $7.50.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.